Pharmafile Logo
Pharmafocus logo
Advanced Search

endometrial cancer

Showing 12 posts of 12 posts found.

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

August 5, 2024
Research and Development GSK, Oncology, Reproductive health, endometrial cancer

PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …

News
Press release

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024
Medical Communications EMA, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand the use of Jemperli (dostarlimab) …

News

AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment

June 17, 2024
Medical Communications AstraZeneca, Imfinzi, Oncology, chemotherapy, endometrial cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) in combination with carboplatin and …

News

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024
Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA

GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …

News

GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment

March 18, 2024
Research and Development GSK, Jemperli, Oncology, clinical trial, endometrial cancer, women's health

GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) …

News

GSK’s Jemperli recommended by NICE for endometrial cancer treatment

March 5, 2024
Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …

News

GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment

December 18, 2023
Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer

GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …

News

GSK’s Jemperli approved in EU as treatment for endometrial cancer

December 11, 2023
Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, …

News

GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment

October 30, 2023
Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed …

News

GSK’s Jemperli approved for treatment of endometrial cancer

August 1, 2023
Research and Development FDA, GSK, Jemperli, Oncology, dostarlimab, endometrial cancer

GSK has announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and …

News

GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer

June 6, 2023
Research and Development GSK, Jemperli, Oncology, endometrial cancer, oncology

GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …

News
shutterstock_212035546

Extended use of breast cancer drug tamoxifen linked to increased endometrial cancer risk

July 9, 2018
Research and Development, Sales and Marketing Cancer, breast cancer, endometrial cancer, pharma, tamoxifen

New evidence published in the British Journal of Surgery has indicated a troubling link between long-term use of the breast …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026